Cargando…

Assesssment of the effect of pretreatment with neoadjuvant therapy on primary breast cancer.

Patients with invasive cancer of the breast (T1-4, N0-2, M0) were assigned to pretreatment based on oestrogen receptor (ER) status; patients with ER-negative tumours received chemotherapy [mitozantrone, methotrexate and mitomycin C (MMM)] for 3 months, patients with ER-positive tumours underwent end...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gazet, J. C., Coombes, R. C., Ford, H. T., Griffin, M., Corbishley, C., Makinde, V., Lowndes, S., Quilliam, J., Sutcliffe, R.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1996
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074387/ https://www.ncbi.nlm.nih.gov/pubmed/8611376

Ejemplares similares

Randomised trial of chemotherapy versus endocrine therapy in patients presenting with locally advanced breast cancer (a pilot study).
por: Gazet, J. C., et al.
Publicado: (1991)

The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer.
por: Stein, R. C., et al.
Publicado: (1990)

Tamoxifen, aminoglutethimide and danazol: effect of therapy on hormones in post-menopausal patients with breast cancer.
por: Coombes, R. C., et al.
Publicado: (1982)

Phase I/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II Clinical Trials Committee study.
por: Stein, R. C., et al.
Publicado: (1990)

Fibreoptic bronchoscopy as an aid to diagnosis of respiratory symptoms in breast cancer patients.
por: Morris, A. J., et al.
Publicado: (1983)

Pretreatment apparent diffusion coefficient does not predict therapy response to neoadjuvant chemotherapy in breast cancer
por: Surov, Alexey, et al.
Publicado: (2020)

Transplantation of Primary Explants of Human Tumour to Mice Treated with Antilymphocyte Serum
por: Phillips, B., et al.
Publicado: (1970)

Excision of both pretreatment marked positive nodes and sentinel nodes improves axillary staging after neoadjuvant systemic therapy in breast cancer
por: Simons, J. M., et al.
Publicado: (2019)

Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool
por: Chia, Y H, et al.
Publicado: (2010)

Human breast-cancer xenografts in immune-suppressed mice.
por: Bailey, M. J., et al.
Publicado: (1980)

Oral contraceptives and survival in breast cancer.
por: Millard, F. C., et al.
Publicado: (1987)

Evaluation of pretreatment ADC values as predictors of treatment response to neoadjuvant chemotherapy in patients with breast cancer - a multicenter study
por: Surov, Alexey, et al.
Publicado: (2022)

Predicting breast cancer response to neoadjuvant chemotherapy using pretreatment diffuse optical spectroscopic texture analysis
por: Tran, William T, et al.
Publicado: (2017)

MRI-Based Radiomics Analysis for the Pretreatment Prediction of Pathologic Complete Tumor Response to Neoadjuvant Systemic Therapy in Breast Cancer Patients: A Multicenter Study
por: Granzier, Renée W. Y., et al.
Publicado: (2021)

Increased detection of mammary carcinoma cells in marrow smears using antisera to epithelial membrane antigen.
por: Dearnaley, D. P., et al.
Publicado: (1981)

Chemotherapy of human breast-carcinoma xenografts.
por: Bailey, M. J., et al.
Publicado: (1980)

Integration of Clinical and CT-Based Radiomic Features for Pretreatment Prediction of Pathologic Complete Response to Neoadjuvant Systemic Therapy in Breast Cancer
por: Tsai, Huei-Yi, et al.
Publicado: (2022)

The Pretreatment Systemic Inflammatory Response is an Important Determinant of Poor Pathologic Response for Patients Undergoing Neoadjuvant Therapy for Rectal Cancer
por: Dreyer, Stephan B., et al.
Publicado: (2016)

Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
por: Byrski, T, et al.
Publicado: (2011)

Predictive Value of Pretreatment Peripheral Neutrophil-to-Lymphocyte Ratio for Response to Neoadjuvant Chemotherapy and Breast Cancer Prognosis
por: Li, Xiaomin, et al.
Publicado: (2021)

Neoadjuvant Therapy for Primary Resectable Retroperitoneal Sarcomas—Looking Forward
por: Istl, Alexandra C., et al.
Publicado: (2022)

The NeST (neoadjuvant systemic therapy in breast cancer) study – Protocol for a prospective multi-centre cohort study to assess the current utilization and short-term outcomes of neoadjuvant systemic therapies in breast cancer
por: Irwin, G.W., et al.
Publicado: (2019)

Transplantation of Human Tumour to Immune Deprived Mice Treated with Anti-thymocyte Serum
por: Detre, S. I., et al.
Publicado: (1973)

An assessment of the effects of hormones on short term organ cultures of human breast carcinomata.
por: Beeby, D. I., et al.
Publicado: (1975)

Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI
por: Braman, Nathaniel M., et al.
Publicado: (2017)

The Tumor–Fat Interface Volume of Breast Cancer on Pretreatment MRI Is Associated with a Pathologic Response to Neoadjuvant Chemotherapy
por: Cho, Hwan-ho, et al.
Publicado: (2020)

Neoadjuvant systemic therapy for breast cancer
por: Zaborowski, Alexandra M, et al.
Publicado: (2023)

Recent advances in neoadjuvant therapy for breast cancer
por: Potter, David A, et al.
Publicado: (2021)

Rapid response of breast cancer to neoadjuvant intramammary testosterone-anastrozole therapy: neoadjuvant hormone therapy in breast cancer
por: Glaser, Rebecca L., et al.
Publicado: (2014)

Biomarkers from in vivo molecular imaging of breast cancer: pretreatment (18)F-FDG PET predicts patient prognosis, and pretreatment DWI-MR predicts response to neoadjuvant chemotherapy
por: Gallivanone, Francesca, et al.
Publicado: (2017)

Pretreatment prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer: Perfusion metrics of dynamic contrast enhanced MRI
por: Lee, Jeongmin, et al.
Publicado: (2018)

Erratum to: Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI
por: Braman, Nathaniel M., et al.
Publicado: (2017)

Pretreatment Systemic Inflammation Response Index in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy as a Useful Prognostic Indicator
por: Chen, Li, et al.
Publicado: (2020)

Pretreatment systemic inflammation response index is predictive of pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy
por: Dong, Jie, et al.
Publicado: (2021)

Pretreatment CT and PET radiomics predicting rectal cancer patients in response to neoadjuvant chemoradiotherapy
por: Yuan, Zhigang, et al.
Publicado: (2021)

Initial experience with targeted axillary dissection after neoadjuvant therapy in breast cancer patients
por: Pinto, C. S., et al.
Publicado: (2022)

Effect of neoadjuvant therapy on breast cancer biomarker profile
por: Rey-Vargas, Laura, et al.
Publicado: (2020)

Is the (Neo)adjuvant Therapy of Patients with Primary HER2-positive Breast Cancer Cost-Covering?: Process Cost Analysis of Neoadjuvant and Post-Neoadjuvant Systemic Therapy of Patients with Primary HER2-positive Breast Cancer
por: Krawczyk, Natalia, et al.
Publicado: (2022)

State of the art in neoadjuvant therapy of breast cancer
por: Minckwitz, Gunter von, et al.
Publicado: (2013)

Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer
por: Fürstenberger, G, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_mff0m67ga2ft8h2sk82er2172s